CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia – nejm.org
From the Sarah Cannon Center for Blood Cancer at the Children’s Hospital at TriStar Centennial, Nashville (H.F., J.D.), and St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; Vertex Pharmaceuticals (D.A., B.K.E., J.L.-H., A.Y.) and Boston University School of Medicine (M.H.S.), Boston, and CRISPR Therapeutics, Cambridge (Y.-S.C., T.W.H., A. Kernytsky, S. Soni) — both in Massachusetts; the University of Milan, Milan (M.D.C.), and Ospedale Pediatrico Bambino Gesù Rome, Sapienza, University of Rome, Rome (F.L.); the University of Regensburg, Regensburg (J. Foell, S.C.), and Children’s University Hospital, University of Tübingen, Tübingen (R.H.) — both in Germany; Imperial College Healthcare NHS Trust, St. Mary’s Hospital, London (J. de la Fuente); Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (S.G.); the University of Athens, Athens (A. Kattamis); BC Children’s Hospital, University of British Columbia, Vancouver (A.M.L.), and the Hospital for Sick Children–University of Toronto, Toronto (D.W.) — both in Canada; Columbia University (M.Y.M.) and the Joan and Sanford I. Weill Medical College of Cornell University (S. Sheth), New York; Necker–Enfants Malades Hospital, Assistance Publique–Hôpitaux de Paris, University of Paris, Paris (M.M.); and the University of Illinois at Chicago, Chicago (D.R.).
Address reprint requests to Dr. Frangoul at the Sarah Cannon Center for Blood Cancer at the Children’s Hospital at TriStar Centennial, 330 23rd Ave. N., Suite 450, Nashville, TN 37203, or at [email protected]; or to Dr. Corbacioglu at Children’s Hospital Regensburg, University of Regensburg, Franz-Josef Strauss Allee 11, 93053 Regensburg, Germany, or at [email protected].
Published at Sat, 05 Dec 2020 17:30:24 +0000